Gent

• Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus I … Ended
  2024-511755-18-00 5 2022-12-23 Invasive Candidiasis/ Candidemia
• A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participant … Ended
  2023-509078-45-00 4 2022-12-19 Multiple sclerosis
• A study to test whether BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder Ended
  2023-506369-79-00 4 2022-11-30 Pancreatic ductal adenocarcinoma
• Phase 3 Study of Tinlarebant in the Treatment in Adolescent Stargardt Subjects Ended
  2024-513483-26-00 5 2022-11-28 Stargardt Disease
• A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended
  2022-500332-11-00 4 2022-11-25 systemic sclerosis
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• VItamin C in Thermal injuRY: The VICToRY Trial A phase III multi-center randomized trial Ended
  2023-504772-21-00 4 2022-11-22 Severely burned patients
• Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat … Ended
  2024-514714-12-00 10 2022-11-11 Metastatic Pancreatic Ductal Adenocarcinoma
• A trial to learn if REGN7999 is safe and well tolerated, and how it works in the body of healthy participants. Ended
  2022-500398-15-00 1 2022-10-24 Healthy - R7999 being developed for the treatment of diseases associa
• A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended
  2024-512803-37-00 5 2022-10-05 Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
• Study of PIT565 in relapsed and/or refractory B-cell malignancies Ended
  2023-507430-25-00 1 2022-10-03 Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and
• A randomized first-in-human, Phase 1, single-center, observer-blind, active-controlled 3-arm study to evaluate the safety, tolerability, and … Ended
  2022-500681-98-00 1 2022-09-14 Influenza
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
• A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08 , an IL-15 Antibody Fusion Protein Targeting CTLA-4, Mo … Ended
  2024-511750-53-00 7 2022-09-08 Unresectable Locally Advanced or Metastatic Cancer
• A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorect … Ended
  2023-503797-21-00 5 2022-08-10 Metastatic Colorectal Cancer
• Cohort study of human mpox virus disease Ended
  2022-501132-42-00 6 2022-08-02 Monkeypox virus disease
• Two-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended
  2024-511069-12-00 5 2022-07-28 Sjögren’s Syndrome
• A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian … Ended
  2023-505005-16-00 4 2022-07-27 Primary peritoneal cancer/Fallopian tube cancer
• Live Attenuated Rift Valley Fever Vaccine for Single Shot Administration (LARISSA) Ended
  2022-501460-17-00 1 2022-07-26 Rift Valley fever (RVF) infection
• A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended
  2023-505455-44-00 9 2022-06-29 Solid tumours
• A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alon … Ended
  2023-506981-30-00 4 2022-05-25 Chronic kidney disease in type 2 diabetes mellitus
• A phase 1/1b/2 study of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors. Ended
  2023-504363-17-00 7 2022-05-13 Advanced MTAP-null solid tumors
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome Ended
  2024-514336-24-00 5 2022-03-24 Familial Chylomicronemia Syndrome (FCS)

Showing 817–840 of 922 trials